Lidocaine can induce Ki-67 degradation in the nucleus of cervical cancer cells, thereby inhibiting the growth of cancer cells, and arrest cervical cancer cells in G1 phase and delay their entry into S phase (Haraguchi-Suzuki et al., 2022). This evidence concerns the gene MKI67 and cervical carcinoma.